Keros Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Lexington, MA
KROS chart
What traders are saying about $KROS
Latest postsKeros Therapeutics, Inc. news
- Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
Yahoo Finance ·
- Weekly Recap: Q3 profit and revenue gains and Phase 3 ELRiSE dosing
TradingView ·
- Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Wall Street Zen
MarketBeat ·
- Keros Therapeutics, Inc. (KROS) Seasonal returns chart
Yahoo Finance UK ·
- Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Beats Estimates By $1.66 EPS
MarketBeat ·
- Keros Therapeutics (KROS) Tops Q3 EPS by 164c
StreetInsider ·
- Keros Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
Yahoo Finance ·
- Keros Therapeutics swings to Q3 profit on Takeda license revenue
TradingView ·
- Keros Therapeutics Reports $14.2 Million Q3 Net Income and Pipeline Progress
TradingView ·
- Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Yahoo Finance ·
- A $259.5 million cash balance is expected to fund Keros' operations into the second half of 2028.
Stock Titan ·
Keros Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M |
| Diluted EPS | $2.30 | $-5.00 | $-5.20 | $-4.15 |
| Total assets (year end) | $338.0M | $615.9M | $370.0M | $306.8M |
| Cash and equivalents (year end) | $287.4M | $559.9M | $331.1M | $279.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Keros Therapeutics, Inc.
- Ticker
- KROS (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Lexington, MA
- Fiscal year end
- December 31
- SEC CIK
- 1664710
Frequently asked questions
What exchange is Keros Therapeutics, Inc. listed on?
Keros Therapeutics, Inc. trades on the Nasdaq under the ticker symbol KROS.
What industry is Keros Therapeutics, Inc. in?
Keros Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Keros Therapeutics, Inc. headquartered?
Keros Therapeutics, Inc.'s business address on file with the SEC is in Lexington, MA.
When does Keros Therapeutics, Inc.'s fiscal year end?
Keros Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Keros Therapeutics, Inc. report?
Keros Therapeutics, Inc. reported $244.1M in revenue for calendar year 2025, according to its SEC filings.